Vimta Labs Ltd
Vimta Labs Q2 Results 2026 (FY27): Guides 20–40% Revenue Growth, Steady Margins
Q2 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #16 of 32 in Healthcare Services
See the sector's top 10 — free with your mobile number.
What the Q2 FY27 call signalled
3 of 4 strong
The short version
Medium-term revenue growth target: INR 700 crores by FY '28 with 35%-36% EBITDA margin. Medium-term revenue growth target: INR700 crores turnover for FY '28, implying ~20-25% CAGR in top line.
From Vimta Labs Ltd's Q2 FY27 earnings-call transcript · updated 4 Nov 2026.
How did Vimta Labs' revenue grow in the September 2026 quarter?
- Medium-term revenue growth target: INR 700 crores by FY '28 with 35%-36% EBITDA margin.
- Anticipated CAGR in top-line: 20%-25%, driven by pharma analytics, preclinical, and biologics segments.
- Signs of recovery seen in pharma R&D pipelines with increasing RFPs and inquiries.
- Growth headwinds currently due to slow pharma R&D pipelines and temporary food segment issues linked to export/import challenges.
- Preclinical segment growing healthily at ~30% CAGR over last 4 years; expected to continue growing with increased animal holding capacity.
- Biologics segment in early stages, expected to contribute significantly over next 2 years.
- Clinical and CRADS services expected to improve in H2 FY '27 supported by active customer discussions.
2 more points from Vimta Labs Ltd's call on revenue
Create a free account to keep reading this call
What happened to Vimta Labs' margins in Q2 FY27?
See what Vimta Labs Ltd said on profitability & margins — free account, 30 seconds.
What capex is Vimta Labs planning?
- Vimta Labs has budgeted approximately INR 80 crores for capex for FY '27, including maintenance capex of around INR 45-50 crores.
- Capex is distributed across business units: preclinical, food, analytical (small molecule and large molecule).
- Current large animal facility in preclinical is at capacity; expansions underway.
- Biologics CRADS business has seen around INR 20 crores invested so far; expects a 1:1 return on investment, but asset turn is too early to confirm.
- Additional reactors required for biologics capacity expansion.
- Capex plans are phased and highly disciplined, depending on business visibility and opportunities.
- Previous exceptional capex of ~INR 100 crores for building infrastructure supports 5-7 years of growth.
2 more points from Vimta Labs Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Vimta Labs raising money or cutting debt?
See what Vimta Labs Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Vimta Labs' order book?
- The company has a healthy pipeline of active customer discussions on proposals, particularly in Contract Research and Development Services (CRADS) for large molecules and clinical research.
- Improvement in CRADS and clinical research is expected during Q3 and Q4, depending on the conversion of these discussions into executable projects.
- The clinical research segment is in the process of rebuilding its customer base, with multiple new contracts signed post some major client losses last year.
2 more points from Vimta Labs Ltd's call on order book
Create a free account to keep reading this call
Vimta Labs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹112 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Vimta Labs's management said in earlier quarters
- Q3 FY25 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
- Q3 FY23 earnings call →
Others in Healthcare Services this season
- Dr Lal Pathlabs Ltd (Q2 FY27)
874 Cr, up 19.6% YoY from Rs. Key investor presentation takeaways from Dr Lal Pathlabs Ltd's Q2 FY27 investor presentation — and how it ranks against sector pee
- Vijaya Diagnostic Centre (Q2 FY27)
Q2 FY27 Revenue from Operations: INR 2,554 Mn, up 26.7% YoY (Page 10, 9) . Key investor presentation takeaways from Vijaya Diagnostic Centre Ltd's Q2 FY27 inves
- Shalby (Q2 FY27)
Consolidated Total Revenue for Q2 FY27: ₹3,182 million vs ₹2,899 million in Q2 FY26, up 9.8% YoY (Pages 5, 6, 8, 9) . Key investor presentation takeaways from S
- Metropolis Healt (Q2 FY27)
Q2FY27 revenue from operations: INR 496.8 Cr, up 15.8% YoY (Page 11) . Key investor presentation takeaways from Metropolis Healthcare Ltd's Q2 FY27 investor pre
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Vimta Labs Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Vimta Labs Ltd Q2 FY27 results?
Medium-term revenue growth target: INR 700 crores by FY '28 with 35%-36% EBITDA margin. Medium-term revenue growth target: INR700 crores turnover for FY '28, implying ~20-25% CAGR in top line.
What is Vimta Labs Ltd share price analysis?
Vimta Labs Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 26.6 with a market cap of ₹2,170 Cr. Investors should review the full earnings analysis for detailed insights.
Is Vimta Labs Ltd planning capital expenditure?
Vimta Labs has budgeted approximately INR 80 crores for capex for FY '27, including maintenance capex of around INR 45-50 crores.
Keep Vimta Labs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.